New guidelines help identify, treat bacterial sinusitis
Approximately 20 million cases of acute bacterial rhinosinusitis (ABRS) are reported in the U.S. every year, and cost the economy almost $3.5 billion annually. In addition, ABRS is the fifth most common diagnosis for which an antibiotic is prescribed. The Sinus and Allergy Health Partnership (SAHP) recently updated its guidelines that provide recommendations for the accurate diagnosis and treatment of ABRS. The updated Antimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis were published in the January 2004 issue of Otolaryngology- Head and Neck Surgery.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
